×
About 17,885 results

Early Risk of Asthma in Children Exposed to In-utero Maternal Obesity
https://clinicaltrials.gov/ct2/show/NCT02903134

Sep 10th, 2021 - The general objectives of this study are: To determine whether the increased risk of asthma in children born from a pre-pregnant obese mother can be observed at 3 years of life and whether this increased risk associated with altered plasma levels of immune mediators at birth. To explore in children born from pre-pregnant obese mother whether monocyte physiology and M1-M2 polarization present an...

Ideal Steroids for Asthma Treatment in the PICU
https://clinicaltrials.gov/ct2/show/NCT03900624

Sep 10th, 2021 - As the pathophysiology of an acute asthma exacerbation is dysregulated inflammatory pathways, standard treatment includes the prompt initiation of intravenous systemic corticosteroids. Corticosteroids reduce the production of many mediators involved in the inflammatory process and inhibit macrophages, monocytes, T-lymphocytes, eosinophils, and basophils, which are activated during this process....

Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
https://clinicaltrials.gov/ct2/show/NCT04828603

Sep 10th, 2021 - The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04800315

Sep 10th, 2021 - The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
https://clinicaltrials.gov/ct2/show/NCT03587805

Sep 10th, 2021 - The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.

COrticosteroids in acUte uRticAria in emerGency dEpartment
https://clinicaltrials.gov/ct2/show/NCT03545464

Sep 10th, 2021 - Acute urticaria (hives) is a common skin disease. The prevalence of acute urticaria in life is about 15 to 20% in the general population. It is responsible for a frequent use of emergency departments (ED). The usual treatment is based on early administration of an association of antihistamines and corticosteroid. The therapeutic efficacy of corticosteroids has never been established by high evi...

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children
https://clinicaltrials.gov/ct2/show/NCT03843437

Sep 10th, 2021 - Atopic dermatitis (eczema) is a chronically recurrent, pruritic disorder most common in infants and young children. It is one of the most common pediatric dermatologic disorders, affecting 15-20% of all children between 6 months and 10 years of age. The vast majority of affected children (up to 85%) have the first outbreak during infancy. The distribution of lesions is characteristically symmet...

Inpatient Penicillin Allergy Delabeling Study
https://clinicaltrials.gov/ct2/show/NCT05020327

Sep 10th, 2021 - A. Specific Aims and Hypotheses General Objective: To verify pediatric patients with reported penicillin allergy in electronic medical record (EMR) by performing direct oral amoxicillin challenge testing. Hypothesis: Pediatric patients with reported penicillin allergy in EMR can be verified by performing direct oral amoxicillin challenge testing. Specific objectives: To identify no-risk, low-ri...

Early Intervention in Allergic Patients
https://clinicaltrials.gov/ct2/show/NCT05040828

Sep 10th, 2021 - As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.

Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab (SASAM Study)
https://clinicaltrials.gov/ct2/show/NCT05040997

Sep 10th, 2021 - Study hypothesis We hypothesize that mepolizumab has a significant beneficial effect on small airways disease in severe asthmatics and that the evaluation of small airways before and during treatment may represent a distinctive marker of response and a novel target for a preferential use of this drug vs other biologics available for severe eosinophilic asthmatic patients. Study objectives To ev...

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04605094

Sep 9th, 2021 - The aim of this study is to investigate the use of benralizumab as treatment for patients with moderate to severe atopic dermatitis (AD) who remain symptomatic despite treatment with topical medications. It is proposed that benralizumab will deplete eosinophils from affected skin, improve symptoms of AD, and improve AD-related quality of life. This Phase 2 study is designed to compare the effic...

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
https://clinicaltrials.gov/ct2/show/NCT04612725

Sep 9th, 2021 - The aim of this study is to investigate the use of benralizumab as treatment for patients with chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines. It is proposed that benralizumab will deplete eosinophils and basophils from affected skin, improve symptoms of CSU, and improve CSU-related quality of life. This Phase 2b study is designed to evaluate induction...

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04587453

Sep 9th, 2021 - Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, health-related quality of life, and health care resource utilis...

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
https://clinicaltrials.gov/ct2/show/NCT04250337

Sep 9th, 2021 - This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
https://clinicaltrials.gov/ct2/show/NCT03373045

Sep 9th, 2021 - The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. This study will provide a contemporary description of the epidemiology and medical management of United States adults with severe a...

Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
https://clinicaltrials.gov/ct2/show/NCT04286542

Sep 9th, 2021 - Patients with perennial allergic rhinitis, chronic rhinosinusitis with nasal polyps and healthy control subjects will be recruited. At baseline, nasal secretions and mucosal biopsies will be collected. After 3 weeks, participants will be provoked with cold, dry air, and samples will be harvested again. A decrease in the peak nasal inspiratory flow of >20% will be used as a cutoff to define nasa...

Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04706559

Sep 9th, 2021 - Atopic dermatitis (AD) is the common chronic inflammatory skin disease with relapsing courses that often start in infancy and childhood. It is characterized by erythema, itchy papules, occasionally vesicles (in infants), which may become excoriated and lichenified and have a typical flexural distribution. Atopy is defined as a "personal or familial tendency to produce immunoglobulin antibodies ...

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria
https://clinicaltrials.gov/ct2/show/NCT04853992

Sep 9th, 2021 - This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and B). Each treatment period will last 7 days with a wash-out period of 7 days between treatments. Half of the subjects will start with treatment A followed by treatment B while the other half will start with trea...

Finding Correlations Between Asthma Exacerbation, Physiological Measurements and Environmental Factors
https://clinicaltrials.gov/ct2/show/NCT04845932

Sep 9th, 2021 - The study aims to identify asthma-related physiological changes observed by wearable devices in real-world conditions. The investigators aim to monitor multiple sensing modalities (e.g., heart rate (HR), heart rate variability (HRV), activity level, spirometry, coughing sounds) in order to find reliable signatures of impending asthma exacerbation and systematically explore any challenges on the...

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
https://clinicaltrials.gov/ct2/show/NCT04987944

Sep 9th, 2021 - This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.